Using Real World Data to Individualize HCV Management

Volume 5, Issue 10.

In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

HBV: Addressing Current Gaps in Diagnosis and Linkage to Care

Volume 5, Issue 2.

Our guests authors are Mindie Nguyen, MD, MAS, from Associate Professor of Medicine at Stanford University, and Dr. Iris Liou, MD of the University of Washington.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Extrahepatic Manifestations of Hepatitis C: Screening and Management

Volume 4, Issue 14.

Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scenarios for the clinical practice.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations

Volume 4, Issue 7.

Drs Paul Martin, MD and Kalyan Ram Bhamidimarri, MD cover the important topic of Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations in the format of case-study scenarios for the clinical practice.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 3.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 2.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 1.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY

Special Edition 2014, Issue 1, Part 2.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy with program director, Dr. Raymond Chung.